{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:02:15Z","timestamp":1784599335286,"version":"3.55.0"},"reference-count":68,"publisher":"ARAN Ediciones","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.hipert.2017.06.001","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T02:16:25Z","timestamp":1499825785000},"page":"176-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inhibidores de PCSK-9, efectos sobre el cLDL e implicaciones futuras: lo que se debe saber"],"prefix":"10.20960","volume":"34","author":[{"given":"P.","family":"Corral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2017.06.001_bib0345","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2017.06.001_bib0350","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCRESAHA.115.306297","article-title":"The success story of LDL cholesterol lowering","volume":"19","author":"Pedersen","year":"2016","journal-title":"Circ Res."},{"key":"10.1016\/j.hipert.2017.06.001_bib0355","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2017.06.001_bib0360","first-page":"16","article-title":"Cardiac risk factors: Environmental, sociodemographic, and behavioral cardiovascular risk factors","volume":"421","author":"Anthony","year":"2014","journal-title":"FPEssent."},{"key":"10.1016\/j.hipert.2017.06.001_bib0365","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2017.06.001_bib0370","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.111.088591","article-title":"Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: The Treating to New Targets (TNT) study","volume":"125","author":"Mora","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2017.06.001_bib0375","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2017.06.001_bib0380","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.hipert.2017.06.001_bib0385","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: What have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.hipert.2017.06.001_bib0390","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.atherosclerosissup.2015.02.039","article-title":"Lipoprotein(a) \u2014An independent causal risk factor for cardiovascular disease and current therapeutic options","volume":"18","author":"Kassner","year":"2015","journal-title":"Atheroscler Suppl."},{"key":"10.1016\/j.hipert.2017.06.001_bib0395","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA."},{"key":"10.1016\/j.hipert.2017.06.001_bib0400","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet."},{"key":"10.1016\/j.hipert.2017.06.001_bib0405","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMp1508120","article-title":"Reducing LDL with PCSK9 inhibitors \u2014The clinical benefit of lipid drugs","volume":"373","author":"Everett","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2017.06.001_bib0410","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Int Med."},{"key":"10.1016\/j.hipert.2017.06.001_bib0415","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase I (NARC-1): Liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.hipert.2017.06.001_bib0420","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"375","author":"Shan","year":"2008","journal-title":"Biochem Biophys Res Comm"},{"key":"10.1016\/j.hipert.2017.06.001_bib0425","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1073\/pnas.0904560106","article-title":"Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels","volume":"106","author":"Steinberg","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hipert.2017.06.001_bib0430","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.hipert.2017.06.001_bib0435","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol."},{"key":"10.1016\/j.hipert.2017.06.001_bib0440","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"Aspectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet."},{"key":"10.1016\/j.hipert.2017.06.001_bib0445","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.hipert.2017.06.001_bib0450","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2017.06.001_bib0455","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease","volume":"55","author":"Benn","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2017.06.001_bib0460","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.hipert.2017.06.001_bib0465","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15420\/ecr.2014.9.2.65","article-title":"The emerging role of PCSK9 inhibitors in preventive cardiology","volume":"9","author":"Pitts","year":"2014","journal-title":"ECR"},{"key":"10.1016\/j.hipert.2017.06.001_bib0470","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/13543784.2012.679340","article-title":"Inhibition of pro-protein convertase subtilisin kexin 9 (PCSK9) as a treatment for hyperlipidaemia","volume":"21","author":"Wierzbicki","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hipert.2017.06.001_bib0475","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1074248414539562","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibitors: An emerging lipid-lowering therapy?","volume":"20","author":"Dragan","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"10.1016\/j.hipert.2017.06.001_bib0480","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":"Lipid lowering with PCSK9 inhibitors","volume":"11","author":"Dadu","year":"2014","journal-title":"Nat Rev Cardiol."},{"key":"10.1016\/j.hipert.2017.06.001_bib0485","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymeth.2005.01.007","article-title":"Design of humanized antibodies: From anti-Tac to Zenapax","volume":"36","author":"Tsurushita","year":"2005","journal-title":"Methods."},{"key":"10.1016\/j.hipert.2017.06.001_bib0490","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.coi.2008.06.004","article-title":"Fully human antibodies from transgenic mouse and phage display platforms","volume":"20","author":"Lonberg","year":"2008","journal-title":"Curr Opin Immunol."},{"key":"10.1016\/j.hipert.2017.06.001_bib0495","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods."},{"key":"10.1016\/j.hipert.2017.06.001_bib0500","unstructured":"Pfizer.com [consultado 1 Nov 2016]. Disponible en: http:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer discontinues global development of bococizumab its investigational pcsk9 inhibitor."},{"key":"10.1016\/j.hipert.2017.06.001_bib0505","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/VHRM.S83719","article-title":"Development of proprotein convertase subtilisin\/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders","volume":"12","author":"Gupta","year":"2016","journal-title":"Vasc Health Risk Manag."},{"key":"10.1016\/j.hipert.2017.06.001_bib0510","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2017.06.001_bib0515","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.hipert.2017.06.001_bib0520","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20082407","article-title":"Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor","volume":"419","author":"Duff","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.hipert.2017.06.001_bib0525","unstructured":"FDA News Release. FDA approves Repatha to treat certain patients with high cholesterol [consultado 24 Sept 2015]. Disponible en: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnounce ments\/ucm460082.htm"},{"key":"10.1016\/j.hipert.2017.06.001_bib0530","unstructured":"FDA News Release. FDA approves Praluent to treat certain patients with high cholesterol[consultado 24 Sept 2015]. Disponible en: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnounce ments\/ucm455883.htm"},{"key":"10.1016\/j.hipert.2017.06.001_bib0535","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: Pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J."},{"key":"10.1016\/j.hipert.2017.06.001_bib0540","unstructured":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). U.S. National Institutes of Health website [actualizado 26 Jul 2016] [consultado 23 Oct 2016]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01764633"},{"key":"10.1016\/j.hipert.2017.06.001_bib0545","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.hipert.2017.06.001_bib0550","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Eficacy and safety of eEvolocumab in reducing lipids and cardiovascular events (Open-Label Study of Long-term Evaluation against LDL Cholesterol Investigators) (OSLER)","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.hipert.2017.06.001_bib0555","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Eficacy and safety of alirocumab in reducing lipids and cardiovascular events (ODYSSEY Long Term Investigators)","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.hipert.2017.06.001_bib0560","unstructured":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab. U.S. National Institutes of Health website [actualizado 23 Oct 2016]. [consultado 13 Sept 2016]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01663402"},{"key":"10.1016\/j.hipert.2017.06.001_bib0565","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.hipert.2017.06.001_bib0570","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehv707","article-title":"Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 (PCSK9): A randomized, placebo controlled Phase 2 study","volume":"37","author":"Kastelein","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2017.06.001_bib0575","series-title":"Inhibition of PCSK9 synthesis via RNA Interference: 90 day data from Orion-1: A multi-centre phase-2 randomized controlled trial","author":"Ray","year":"2016"},{"key":"10.1016\/j.hipert.2017.06.001_bib0580","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70mg\/dL: Lower is better and physiologically normal","volume":"43","author":"O\u2019Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2017.06.001_bib0585","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: A meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Medicine."},{"key":"10.1016\/j.hipert.2017.06.001_bib0590","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1161\/CIRCULATIONAHA.116.023687","article-title":"Pleiotropic effects of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors?","volume":"134","author":"Bittner","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.hipert.2017.06.001_bib0595","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1093\/eurheartj\/ehw346","article-title":"PCSK9 inhibitors diabetes risk: A question worth asking?","volume":"37","author":"Sattar","year":"2016","journal-title":"Eur Heart F J."},{"key":"10.1016\/j.hipert.2017.06.001_bib0600","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1471-4159.2006.03928.x","article-title":"Implication of the proprotein convertase NARC-1\/PCSK9 in the development of the nervous system","volume":"98","author":"Poirier","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.hipert.2017.06.001_bib0605","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J Innate Immun"},{"key":"10.1016\/j.hipert.2017.06.001_bib0610","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology."},{"key":"10.1016\/j.hipert.2017.06.001_bib0615","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.22130","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells","volume":"224","author":"Lan","year":"2010","journal-title":"J Cell Physiol."},{"key":"10.1016\/j.hipert.2017.06.001_bib0620","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem."},{"key":"10.1016\/j.hipert.2017.06.001_bib0625","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.22911","article-title":"PCSK9 impedes hepatitis C virus infection in vitro and modu- lates liver CD81 expression","volume":"50","author":"Labonte","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.hipert.2017.06.001_bib0630","doi-asserted-by":"crossref","first-page":"19266","DOI":"10.1074\/jbc.M112.363382","article-title":"Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"287","author":"Sharotri","year":"2012","journal-title":"J Biol Chem."},{"key":"10.1016\/j.hipert.2017.06.001_bib0635","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.hipert.2017.06.001_bib0640","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.hipert.2017.06.001_bib0645","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2016.02.011","article-title":"Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature","volume":"247","author":"Kolodziejczak","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hipert.2017.06.001_bib0650","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hipert.2017.06.001_bib0655","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 Forum. PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"Chapman","year":"2015","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.hipert.2017.06.001_bib0660","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.hipert.2017.06.001_bib0665","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","article-title":"PCSK9 association with lipoprotein (a)","volume":"119","author":"Tavori","year":"2016","journal-title":"Circ Res."},{"key":"10.1016\/j.hipert.2017.06.001_bib0670","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2014.07.010","article-title":"PCSK9 levels in abdominally obese men: Association with cardiometabolic risk profile and effects of a one-year life- style modification proram","volume":"236","author":"Arsenault","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hipert.2017.06.001_bib0675","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/M15-2994","article-title":"Proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies for acute coronary syndrome: A narrative review","volume":"164","author":"Navarese","year":"2016","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.hipert.2017.06.001_bib0680","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188918371730048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188918371730048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:02Z","timestamp":1784596502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S188918371730048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S188918371730048X"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2017.06.001","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibidores de PCSK-9, efectos sobre el cLDL e implicaciones futuras: lo que se debe saber","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2017.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}